INTERIM REPORT CHRONTECH PHARMA JANUARY-MARCH 2010

INTERIM REPORT CHRONTECH PHARMA JANUARY-MARCH 2010

•	Research and development costs amounted to SEK 1.8 (1.1) m
•	The loss after tax was SEK -2.7 (-3.5) m
•	Earnings per share were SEK -0.04 (-0.10)
•	The company had no net sales for the period 
•	The ChronVac-C® study has been finalized and showed that the therapeutic
vaccine is safe and gave positive clinical data. Two patients in the ChronVac-C®
study have received one more dose approximately 6-12 months after the fourth
vaccination and analysis of the results are ongoing. Five of six patients who
after completing the ChronVac-C® study have started treatment according to
standard of care, i.e. interferon in combination with ribavirin have responded
to the treatment with eradication of the virus already after 4 weeks (so called
rapid viral response). This is an unusually rapid reduction of virus in the
blood  indicating a role for ChronVac-C® in combination therapy

              EVENTS AFTER THE END OF THE REPORTING PERIOD
•	The multi-center study on one week´s treatment with ChronSeal® is now
completed and are now being analysed in Sweden and by Kringle in Japan.
ChronTech and Kringle have together decided that the results will be published
on May 27th.



For more information, please contact:
Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, 
E-mail: anders.vahlne@ki.se


About ChronTech
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs
against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic
infections with jaundice causing viruses which can lead to liver cirrhosis and
liver cancer. ChronTech has also developed and further develops a patent pending
new type of injection needle for a more effective uptake of DNA vaccines.
ChronTech also have part ownership in the wound healing therapy ChronSeal®, and
in the new platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium AB is Certified Adviser for ChronTech. For more information,
please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.